Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, ...
Morningstar

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and ...

No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment ...
Hosted on MSN

MPESB Group 4 recruitment 2025: Direct link to apply for 966 posts of Assistant grade 3, Steno Typist and more

MPESB Group 4 recruitment 2025: The Madhya Pradesh Examination Board (MPESB) has opened registrations for the Group 4, Assistant Grade-3, Steno-typist, Stenographer, and Other Post Combined ...